Literature DB >> 12021632

C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects.

David I Min1, Vicki L Ellingrod.   

Abstract

To determine the relationship between C3435T mutation in exon 26 of the human multidrug resistant 1 (MDR1) gene and cyclosporine pharmacokinetic parameters among healthy volunteers, the oral cyclosporine pharmacokinetic study was performed for 14 healthy subjects. Blood cyclosporine concentrations were measured by HPLC. Concentration-time data were analyzed by a noncompartmental method using WinNonLin, and the blood samples were genotyped for the C3435T polymorphism of MDR1 gene using the PCR and a restriction digest. Each cyclosporine pharmacokinetic parameter was compared using the Mann-Whitney U test according to his or her P-gp genotype. There were seven (7) homozygous C/C, six (6) C/T, and one (1) homozygous T/T genotypes in these 14 healthy volunteers. According to their genotypes, mean t(max) 1.6 +/- 0.3 hours, mean C(max) 1337 +/- 329 ng/mL, mean Cl/F 66.5 +/- 18.3 L/h, and mean AUC 5642 +/- 1577 ng.h/mL in C/C group and mean t(max) 2.0 +/- 0.6 hours, mean C(max) 1540 +/- 721 ng/mL, mean Cl/F 55.2 +/- 18.9 L/h, and mean AUC 6902 +/- 1405 ng.h/mL in C/T+T/T group. Although Cmax and AUC in C/T and T/T group were 15% and 22% larger than those in C/C group, none of these parameter comparisons was statistically significant. There were no statistical differences in cyclosporine pharmacokinetics among different MDR1 genotypes in these 14 healthy subjects.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12021632     DOI: 10.1097/00007691-200206000-00012

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  9 in total

Review 1.  Role of P-glycoprotein in pharmacokinetics: clinical implications.

Authors:  Jiunn H Lin; Masayo Yamazaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis.

Authors:  V Annese; M-R Valvano; O Palmieri; A Latiano; F Bossa; A Andriulli
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

3.  Impact of citrus soft drinks relative to grapefruit juice on ciclosporin disposition.

Authors:  Ute I Schwarz; Philip E Johnston; David G Bailey; Richard B Kim; Gail Mayo; Aaron Milstone
Journal:  Br J Clin Pharmacol       Date:  2006-10       Impact factor: 4.335

Review 4.  Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.

Authors:  Jörn Lötsch; Carsten Skarke; Jürgen Liefhold; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

5.  Phase I evaluation of the safety, pharmacokinetics and pharmacodynamics of CP-481,715.

Authors:  Alan T Clucas; Ajit Shah; Yuanchao Derek Zhang; Vincent F Chow; Ronald P Gladue
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

6.  MDR1 polymorphisms effect cyclosporine AUC0-4 values in Behçet's disease patients.

Authors:  Yoshihiko Katsuyama; Masao Ota; Nobuhisa Mizuki; Akiko Ito; Eiichi Okada; Shigeaki Ohno; Tamihide Matsunaga; Hirofumi Fukushima; Shigeru Ohmori
Journal:  Clin Ophthalmol       Date:  2007-09

Review 7.  The MDR1 (ABCB1) gene polymorphism and its clinical implications.

Authors:  Ichiro Ieiri; Hiroshi Takane; Kenji Otsubo
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 8.  Meta-Analysis of ABCB1 3435C>T Polymorphism and Colorectal Cancer.

Authors:  Dan Zhang; Cun Wang; Zongguang Zhou
Journal:  Pak J Med Sci       Date:  2013-09       Impact factor: 1.088

9.  Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters.

Authors:  Johannes Matthaei; Mladen V Tzvetkov; Valerie Gal; Cordula Sachse-Seeboth; Daniel Sehrt; Jakob B Hjelmborg; Ute Hofmann; Matthias Schwab; Reinhold Kerb; Jürgen Brockmöller
Journal:  Genome Med       Date:  2016-11-08       Impact factor: 11.117

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.